LBRXLB PHARMACEUTICALS INCvs its industry peers
A metric-by-metric comparison of LB PHARMACEUTICALS INC against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LBRX본 종목 | $1.4B#4 | 1.8x#1 | 4.1x#6 | — | — | 60.1%#3 | — | -7.6%#4 | — | — | 156.8%#3 | — |
| DMRA | $1.5B#1 | 3.2x#2 | 2.9x#3 | — | — | -878.8%#5 | — | -40.7%#6 | — | — | — | — |
| AVLN | $1.5B#2 | — | 3.7x#4 | — | — | — | — | 0.0%#1 | — | — | — | — |
| AVBP | $1.4B#3 | — | 3.8x#5 | — | — | -106.6%#4 | — | -45.3%#7 | — | — | 60.4%#4 | — |
| OMER | $1.3B#5 | 10.5x#3 | — | 17.9x#2 | -34.0%#2 | 97.9%#1 | -166.4%#2 | — | -151.8%#2 | — | 348.2%#2 | — |
| HROW | $1.2B#6 | — | 81.5x#7 | 4.5x#1 | 36.4%#1 | 70.6%#2 | 11.2%#1 | -33.8%#5 | 13.2%#1 | 6#1 | -23.3%#5 | — |
| AKTS | $1.2B#7 | — | 2.5x#1 | — | — | — | — | 0.0%#1 | — | — | 24643.2%#1 | — |
| SPTX | $1.2B#8 | — | 2.7x#2 | — | — | — | — | 0.0%#1 | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice